Investigating Plasma Biomarker Molecules Associated With the Progression of Prediabetes to Overt Type 2 Diabetes
Biomarkers Identification for the Progression From Pre-diabetes to T2D
There are an estimate 7 million people in the United Kingdom living with pre-diabetes. The increasing number of new cases of pre-diabetes presents a global health concern due to funding implications.
The progression from pre-diabetes to overt type 2 diabetes is often characterised by a reduction in insulin secretion (or β-cell dysfunction). Whilst inflammation may contribute to β-cell dysfunction, a complete picture is still lacking. The proposed research will help develop a more complete understanding of the molecules that may trigger β-cell failure, a process that often connects pre-diabetes to overt diabetes.
The aims of this project are;
- Run large-scale proteomics and metabolomics analysis in pre-diabetic individuals to determine possible biomarker molecules.
- Use measures and / or classifications of insulin resistance and diabetes (i.e. β-cell function and Disposition Index) to establish whether particular metabolic and / or proteomic signatures (aim 1) are associated with the development of pre-diabetes.
- To determine if the possible metabolite or protein profile changes are associated with the progression or regression of pre-diabetes from baseline (0 month) to the end of the National Diabetes Prevention Programme (NDPP) (9 month).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterised by elevated blood sugar. This represents a worldwide concern due to the secondary complications associated with type 2 diabetes, which are considered an important cause of early death; particularly, given the predicted increase. The cost associated with the treatment and the complications associated with diabetes reaches £10 billion every year and it is expected to increase. From approximately 425 million (2017) it is projected that 629 million adults will be living with diabetes by 2045. Therefore, this matter requires effective interventions aimed at improving blood sugar control, reducing the burden on the economy while improving the quality of life among T2DMs.
Insulin, a hormone that is allowing the body to use or store sugar derived from food, is manufactured by the β-cells in the pancreas. The progression from pre-diabetes to overt type 2 diabetes is typically diagnosed at the point of β-cell failure. Several factors are known to contribute to β-cell dysfunction such as: obesity (especially abdominal obesity), high blood pressure and elevated fats in the blood. Around 80% of the people who have been diagnosed with T2DM are either obese or overweight and they have been observed to have increased levels of fatty acids in the blood following a meal, which can induce insulin resistance. High levels of fatty acids have also been associated with an increased production of pro-inflammatory cytokines, which are small proteins that have an effect on organs or other cells, contributing to chronic inflammation. High levels of chronic inflammation increase the chances of developing metabolic disorders such as T2DM. However, a complete picture of this process is still lacking.
The proposed study will help develop a more complete understanding of the molecules that may trigger β-cell failure.
The identification of these molecules that are implicated in β-cell failure, can lead to the development of targeted interventions for those at risk of developing type 2 diabetes and potentially preventing habitual hyperglycaemia and type 2 diabetes.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Richard W Mackenzie
- Telefonnummer: +447985749102
- E-Mail: richard.mackenzie@roehampton.ac.uk
Studienorte
-
-
-
London, Vereinigtes Königreich, SW15 4JD
- Rekrutierung
- University of Roehampton
-
Kontakt:
- Richard Mackenzie, Dr.
- Telefonnummer: 07985749102
- E-Mail: Richard.Mackenzie@roehampton.ac.uk
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
Pre-diabetic individuals between 18 and 65 years of age
Pre-diabetes criteria:
- Glycated hemoglobin (HbA1c) values between 42 - 47 mmol/mol
- Fasting plasma glucose levels between 6.1 - 6.9 mmol/L
- Blood pressure <140 mmHg systolic/ <90 mmHg diastolic
Exclusion Criteria:
- Individuals suffering from any complications (i.e. nerve or kidney disorders, damage of the retina, vascular diseases, strokes, persistent high blood pressure, cardiovascular disease,haemophilia), those with anaemia, blood borne diseases, those who are pregnant or in the postpartum period (within 3 months after delivery), have high blood pressure >140 mmHg systolic/ >90 mmHg diastolic, current smokers, individuals requiring strong anticoagulant medication, such as warfarin (the anticoagulant effect of non-steroidal anti-inflammatory drugs is too small to pose a hazard), insulin or other medications affecting the typical levels of blood glucose are unfortunately unable to take part in this study. Individuals must not be involved in any other study which involves the sampling of blood and must not have donated blood in the last 12 weeks (for males) or 16 weeks (for females). A health questionnaire will be carried out to confirm your eligibility for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Pre Diabetics
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Body weight Measurements
Zeitfenster: Changes from baseline to 6 and 9 months
|
Weight in kilograms
|
Changes from baseline to 6 and 9 months
|
|
Body mass Index measurements
Zeitfenster: Changes from baseline to 6 and 9 months
|
kg/m^2
|
Changes from baseline to 6 and 9 months
|
|
Changes in insulin and glucose
Zeitfenster: Changes from baseline to 6 and 9 months
|
Effect of insulin and glucose levels expressed in mg/dl
|
Changes from baseline to 6 and 9 months
|
|
Changes in BCAA and its derivatives
Zeitfenster: Changes from baseline to 6 and 9 months
|
metabolites levels via mass spectrometry analysis
|
Changes from baseline to 6 and 9 months
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003 Jan 1;289(1):76-9. doi: 10.1001/jama.289.1.76.
- Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988 Aug;37(8):1020-4. doi: 10.2337/diab.37.8.1020.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- LSC 20/ 311
- 245301 (Andere Kennung: IRAS ID)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Typ 2 Diabetes mellitus
-
State University of New York at BuffaloMedical University of South CarolinaAbgeschlossenDiabetes Mellitus | Typ 2 Diabetes mellitus | Altersdiabetes mellitus | Nicht insulinabhängiger Diabetes mellitus | Nicht insulinabhängiger Diabetes Mellitus, Typ IIVereinigte Staaten
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes Typ1 | Diabetes mellitus Typ 1 | Autoimmundiabetes | Diabetes mellitus, insulinabhängig | Jugenddiabetes | Diabetes, Autoimmun | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | Diabetes mellitus, spröde | Diabetes mellitus... und andere BedingungenVereinigte Staaten
-
Guang NingRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ1 | Monogenetischer Diabetes | Pankreatogener Diabetes | Medikamenteninduzierter Diabetes mellitus | Andere Formen von Diabetes mellitusChina
-
Medtronic MiniMed, Inc.RekrutierungGATEWAY: Sicherheitsbewertung des MiniMed™ NMX8-AID-Systems bei Kindern und Erwachsenen mit DiabetesTyp 2 Diabetes mellitus | Diabetes mellitus Typ 1Vereinigte Staaten, Australien, Neuseeland
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
Hoffmann-La RocheRoche DiagnosticsAbgeschlossenDiabetes mellitus Typ 2, Diabetes mellitus Typ 1Deutschland
-
Meir Medical CenterAbgeschlossenDiabetes mellitus Typ 2 | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, zur oralen hypoglykämischen Behandlung | Diabetes mellitus vom ErwachsenentypIsrael
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAbgeschlossenDiabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | IDDMVereinigte Staaten, Australien
-
Vanderbilt University Medical CenterRekrutierungHyperglykämie | Typ-2-Diabetes mellitus (T2DM) | Typ-1-Diabetes mellitus (T1DM)Vereinigte Staaten
-
Insulet CorporationRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ 1Vereinigte Staaten